Non-invasive biomarker specific for Crohn's disease diagnosis

Description:

Serum miRNA panel for non-invasive diagnosis and monitoring of Crohn’s disease

 

Market Need

 

Approximately 1.6 billion people in the US alone have inflammatory bowel disease, which includes Crohn’s disease. These chronic diseases, which have a significant impact on quality of life, can be treated but not cured. According to estimates based on insurance claims data, the direct annual cost of Crohn’s disease ranges from 8 -18 thousand dollars per patient, including the cost of lengthy diagnostic procedures for the disease. Because inflammation in Crohn’s can affect any part of the GI tract, it presents multi-symptomatically and many tests, including invasive endoscopy, biopsy, and radiological testing, are used to confirm diagnosis before treatment. Thus, there is a need for a non-invasive and more accurate means to diagnose Crohn’s disease.

 

Technology Overview

 

The Friedman lab has discovered that the expression of eleven specific miRNAs in a patient’s serum correlate specifically with Crohn’s disease. The miRNA panel was discovered in a cohort of Crohn’s patients when compared to control and the eleven specific miRNAs were confirmed using real-time RT-PCR. These eleven markers were then verified to be increased 2.7-8.7 fold in a second independent cohort of 46 patients of Crohn’s disease compared to healthy patients. To confirm that the miRNAs were specific to Crohn’s disease and not just intestinal inflammation, the same biomarkers were confirmed to be overexpressed in a third independent set of Crohn’s disease patients compared to celiac disease patients. Thus, this panel of serum miRNA biomarkers provides non-invasive confirmation of Crohn’s disease that would be useful for rapid diagnosis and monitoring of the disease.

 

Advantages

•       Non-invasive biomarker present in urine

•        Biomarker is specific to Crohn’s disease compared to general GI inflammation or celiac disease

•       Amenable to point-of-care diagnostic

 

Application

•       Diagnosis of Crohn’s Disease

•       Monitoring treatment of Crohn’s Disease

 

Stage of Development: In vivo proof of concept

  

Case ID:
0463-10-Friedman
Web Published:
2/3/2017
Patent Information:
Title Country Serial No. Patent No. File Date Issued Date
Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease Australia 2011312504   9/27/2011  
Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease Canada 2,812,940   9/27/2011  
Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease Europe 11831280.0   9/27/2011  
Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease Israel 225519   9/27/2011  
Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease Japan 2013-531711   3/27/2013  
Compositions and Methods Useful for the Treatment and Diagnosis of Inflammatory Bowel Disease United States 13/851,623 9,279,158 3/27/2013 3/8/2016
Category(s):
Diagnostic
For Information, Contact:
Cassie Tran
Licensing Associate
The Children's Hospital of Philadelphia
trancm@email.chop.edu
Inventors:
Joshua Friedman
Adam Zahm
Meena Thayu
Nicholas Hand
Edwin de Zoeten
Keywords:
Chronic Disease
Diagnostics